Per-patient delay of 3 or 6 months would result in an estimated 92,214 or 208,275 life-years lost.
Cancer is among the underlying conditions that increase risk for COVID-19.
New findings suggest that the HSD3B1 genotype can be used to risk stratify white men with low-volume metastatic prostate cancer.
About 45 weeks needed to clear surgery backlog if countries up surgical volume by 20% later.
Rates of regional- and distant-stage prostate cancer increasing in the US among men older than 50 years.
The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
TMPRSS2, a serine protease expressed in prostate and lung tissue that is necessary for SARS-CoV-2 viral infectivity of host cells, is activated by the androgen receptor.
Mortality lower despite common opioid prescriptions for cancer-related pain.
FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.
Findings based on survey of American Cancer Society research grantees.